Last reviewed · How we verify
the first donor's stem cell
At a glance
| Generic name | the first donor's stem cell |
|---|---|
| Sponsor | huishengai |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Hepatic Artery Infusion of CD34+ Cells (PHASE1)
- Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer (PHASE2)
- Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- the first donor's stem cell CI brief — competitive landscape report
- the first donor's stem cell updates RSS · CI watch RSS
- huishengai portfolio CI